VR Logo

Sorrento Therapeutics Inc. (SRNE) download report


Healthcare | Biotechnology & Pharma Research

Sorrento Therapeutics Inc. (SRNE) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases.

IPO Date: 11-Jan-2010

Chairman, Pres & CEO: Dr. Henry H. Ji Ph.D.

Exec. VP, CFO & Chief Bus. Officer: Ms. Elizabeth Adkins Czerepak M.B.A.

Listing: NASDAQ: SRNE

Country: United States

Headquarters: San Diego, CA

Website: https://www.sorrentotherapeutics.com

Key Facts

Market cap: $1,073.49 Mln

Revenue (TTM): $57.03 Mln

Earnings (TTM): $-471.65 Mln

Cash: $270.66 Mln

Total Debt: $248.88 Mln

Insider's Holding: 5.79%

Liquidity: Low

52 Week range: $1.15 - 9.63

Shares outstanding: 388,945,984

10 Years Aggregate:

  • CFO: $-987.31 Mln
  • EBITDA: $-1,229.71 Mln
  • Net Profit: $-1,381.41 Mln

Stock Performance

Time Period Sorrento Therapeutics (SRNE) S&P BSE Sensex* S&P Small-Cap 600*
YTD-40.651.11-11.58
1 month28.378.718.86
3 months59.547.41-2.19
1 Year-66.468.51-6.23
3 Years4.9117.099.73
5 Years8.3312.797.72
10 Years-11.5112.8410.81
As on 05-Aug-2022 *As on 08-Aug-2022
Year Sorrento Therapeutics (SRNE) S&P Small-Cap 600 S&P BSE Sensex
2021-31.8725.2721.99
2020101.929.5715.75
201940.8320.8614.38
2018-36.68-9.705.87
2017-22.4511.7327.91
2016-43.7424.741.95
2015-13.51-3.36-5.03